More from the EAU annual meeting in Munich

UroToday has provided a second set of reports on the key presentations given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. … READ MORE …

Prediction of the “real” risk of death from prostate cancer

A while ago now we first discussed research being done by Eric Feuer and others on what was initially being called the Cancer Survival Query System or CSQS. … READ MORE …

Over-treatment of older men with life expectancies < 10 years

According to a paper newly published in Cancer, “Men aged < 80 years at diagnosis who have life expectancies < 10 years often receive aggressive treatment for low-risk and intermediate-risk prostate cancer, mostly with radiation therapy.” … READ MORE …

The benefit (or lack thereof) of early, aggressive treatment in men ≥ 66 years

A new study published on line in the journal Cancer has shown that (a) the cancer-specific survival benefit associated with aggressive treatment for early-stage prostate cancer is reduced with increasing co-morbidity at time of diagnosis, and (b) patients with Charlson scores ≥ 3 gain no survival benefit from aggressive treatment. … READ MORE …

The personalization of prostate cancer management: a way to go yet!

A new study just published in the Journal of General Internal Medicine makes a strong case for the importance of individualized application of specific treatments to older men diagnosed with prostate cancer — something which you would think ought to be evident to the majority of clinicians, but apparently wasn’t … READ MORE …

Co-morbidity, age, mortality, and early-stage prostate cancer

New data from Peter Albertsen and his colleagues at the University of Connecticut have emphasized the importance of thorough assessment of the health status and co-morbidities of older men who are diagnosed with prostate cancer before making decisions about appropriate management. … READ MORE …

Age and co-morbidity as risk factors for over-treatment of low-risk prostate cancer

In recent years, it has become increasingly well understood that patients diagnosed with low-risk prostate cancer are potentially susceptible to over-treatment. This is particularly the case among men who have significant degrees of co-morbidity and men greater than 75 years of age who have a life expectancy of < 15 years. … READ MORE …

Co-morbidity and management of the man with low-risk, localized prostate cancer

At the beginning of November, we commented on a re-analysis of the PLCO data by Crawford et al. — a re-analysis that focused on the impact of co-morbidities on treatment and outcomes over time. … READ MORE …